Please assess the completion status of the following clinical trial:

Trial Title: A Study in Participants With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of RA of more than 6 months and less than 15 years~* At least 8 tender and swollen joints~* An abnormally high C-reactive protein (CRP) level or erythrocyte sedimentation rate (ESR)~* Positive for rheumatoid factor (RF) or anti-cyclic citrullinated peptide (CCP) antibody~* Previously treated with biologic TNF-α inhibitor therapy (infliximab, certolizumab, golimumab, etanercept, adalimumab) and stopped treatment due to insufficient efficacy or intolerance~* Regular use of at least 1 conventional disease-modifying anti-rheumatic drug (DMARD), with a stable dose for at least 8 weeks prior to study start~* Woman must not be pregnant, breastfeeding, or become pregnant during the study~Exclusion Criteria:~* Use of unstable doses of non-steroidal anti-inflammatory drugs (NSAIDS) in the past 6 weeks~* Steroid injection or intravenous (IV) infusion in the last 6 weeks~* Use of more than 10 milligrams/day (mg/day) of oral steroids in the last 6 weeks~* History of a serious reaction to other biological DMARDs~* Use of an oral calcineurin inhibitor (for example, cyclosporin or tacrolimus) in the last 8 weeks~* Surgery on a joint or other major surgery less than 2 months ago, or plans to have joint surgery or major surgery during the study~* Active fibromyalgia, juvenile chronic arthritis, spondyloarthropathy, Crohn's disease, ulcerative colitis, psoriatic arthritis, or other systemic inflammatory condition except RA~* Cervical cancer or squamous skin cancer within the past 3 years, or other cancer within the past 5 years~* Received a live vaccine received within the past 12 weeks (for example, vaccines for measles, mumps, rubella, and chicken pox, and nasal-spray flu vaccines)~* Hepatitis or human immunodeficiency virus (HIV)~* A serious bacterial infection (for example, pneumonia or cellulitis) within 3 months or a serious bone or joint infection within 6 months~* Symptoms of herpes zoster or herpes simplex within the last month~* Active or latent tuberculosis (TB)~* Current symptoms of a serious disorder or illness~* Use of an investigational drug within the last month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 120 milligrams (mg) LY2127399 (Type: EXPERIMENTAL): Given every 4 weeks (Q4W) for 24 weeks. Participants receive a 240-mg loading dose when initiating treatment.~During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks (Q2W).~At Week 16, responders will receive 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period.~At Week 16, non-responders (NR) will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.
- 90 mg LY2127399 (Type: EXPERIMENTAL): Given Q2W for 24 weeks. Participants receive a 180-mg loading dose when initiating treatment.~At Week 16, both responders and NR will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.
- Placebo (Type: PLACEBO_COMPARATOR): Given Q2W for 24 weeks. Participants receive 2 injections of placebo when initiating treatment.~At Week 16, responders will receive 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.~At Week 16, NR will receive a 180-mg loading dose of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).